0001209191-23-042654.txt : 20230718 0001209191-23-042654.hdr.sgml : 20230718 20230718191423 ACCESSION NUMBER: 0001209191-23-042654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coulie Bernard CENTRAL INDEX KEY: 0001808895 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39303 FILM NUMBER: 231095319 MAIL ADDRESS: STREET 1: C/O PLIANT THERAPEUTICS, INC. STREET 2: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001746473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474272481 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-481-6770 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-14 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001808895 Coulie Bernard C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO 0 Common Stock 2023-07-14 4 A 0 137500 0.00 A 412253 D Common Stock 409317 I See footnote On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 137,500 shares. Shares are held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. /s/ Mike Ouimette, attorney-in-fact 2023-07-18